A Review of the Use of Infliximab to Manage Cutaneous Dermatoses

@article{Gupta2004ARO,
  title={A Review of the Use of Infliximab to Manage Cutaneous Dermatoses},
  author={Aditya K. Gupta and Alayne R. Skinner},
  journal={Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology},
  year={2004},
  volume={8},
  pages={77-89}
}
BackgroundInfliximab is a chimeric monoclonal antibody that binds specifically to human tumor necrosis factor-alpha (TNF-α), decreasing the effect of the cytokine in inflammatory diseases.ObjectiveThe aim of this study was to review the efficacy and safety of infliximab in the treatment of dermatological diseases.MethodsA MEDLINE search (1966–January 2003), using the keyword “infliximab” was performed to find relevant articles pertaining to the use of infliximab in dermatology.ResultsInfliximab… 
Lymphoedematous variants of Kaposi's sarcoma
  • L. Pantanowitz, W. Duke
  • Medicine, Biology
    Journal of the European Academy of Dermatology and Venereology : JEADV
  • 2008
TLDR
The beneficial effects of infliximab may support the hypothesis of a possible role of TNFα in the pathophysiolgical mechanism of PRP.
Infliximab in dermatological treatment: beyond psoriasis
TLDR
The possible future uses of infliximab in dermatology are being reviewed, and its TNF-α binding capacity is being reviewed.
Infliximab-induced discoid lupus erythematosus
TLDR
A case of rheumatoid arthritis which developed a discoid lupus erythematosus-like eruption linked to its use after treatment with infliximab is presented.
Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis.
TLDR
Infliximab is a chimeric monoclonal antibody with human and mouse components that binds specifically to both soluble and membrane-bound TNF-α, which implies that a selective T NF-α blockade could be a new and promising type of treatment.
The use of infliximab in dermatology
  • S. Rott, U. Mrowietz
  • Medicine, Biology
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • 2007
TLDR
Autoimmune diseases like Crohn's disease, rheumatoid arthritis (RA) and psoriasis are often difficult to treat due to complex underlying immunologic pathways, and especially infliximab became widely used.
Infliximab and Golimumab
TLDR
This chapter provides a comprehensive review of the safety and efficacy of two of the monoclonal antibody tumor necrosis factor alpha (TNFα) blocking drugs.
Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases
  • S. Moschella
  • Medicine
    International journal of dermatology
  • 2007
TLDR
Hidradenitis suppurativa is one of the follicular occlusion diseases favoring the flexural areas of the body and there is a need for effective medical anti‐inflammatory therapy to control the disease and minimize the pathologic and socioeconomic consequences of the disease process.
Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximab
TLDR
This is the first case of classic juvenile-onset PRP (type III) dramatically improved following anti-tumour necrosis factor-α (TNFα) therapy and a significant reduction of the erythema, itch, and desquamation was observed at the second infusion.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 113 REFERENCES
The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases.
TLDR
Two patients with recalcitrant psoriasis that was unresponsive to multiple skin-directed and systemic therapies were treated with a single infusion of infliximab, an immunoglobulin monoclonal antibody that binds and inactivates TNF-alpha, and improved the symptoms of psoriatic arthritis.
Treatment of Complicated Sarcoidosis with Infliximab AntiTumor Necrosis Factor- Therapy
TLDR
An unusual case of sarcoidosis, manifested by severe protein-losing enteropathy and proximal myopathy, in which the patient responded dramatically to infliximab therapy, which was complicated by the development of hypercoagulability associated with anticardiolipin antibodies.
Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease).
TLDR
A 79-year old woman presented with a 7-year history of subcorneal pustular dermatosis (SPD), which was resistant to multiple therapeutic trials including colchicine, retinoids, systemic glucocorticosteroids, UV phototherapy, azathioprine, and azulfidine.
Response of Severe Psoriasis to Infliximab
TLDR
Treatment was started with the humanized anti-tumour necrosis factor-alpha (TNF-·) monoclonal antibody infliximab (Remicade®, Essex Pharma, München, Germany) and Dramatic improvement of both psoriatic lesions and arthritis was observed already 2 weeks after the first infusion.
Behçet’s disease: a new target for anti-tumour necrosis factor treatment
  • P. Sfikakis
  • Medicine
    Annals of the rheumatic diseases
  • 2002
TLDR
Preliminary results strongly suggest that infliximab is remarkably effective in inducing short-term remission of almost all manifestations of Behçet’s disease, including acute, sight threatening panuveitis.
Drug‐induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N‐acetylcysteine
TLDR
The specific reactivation of a dermatosis following treatment with recombinant cytokines may provide an insight into the immunopathophysiology of the induced eruption seen in the cases described, and should be interpreted with caution.
Successful treatment of SAPHO syndrome with infliximab: report of two cases
TLDR
Two patients affected by refractory SAPHO syndrome with infliximab were treated, both patients had chest pain limiting normal activity despite adequate treatment with NSAIDs and second line treatment was unsuccessful.
Refractory neurosarcoidosis responding to infliximab
TLDR
A case of refractory neurosarcoidosis is described in which the patient responded dramatically to infliximab therapy, a chimeric monoclonal human-murine antibody directed against TNFα.
Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab.
TLDR
Although psoriasis tends to recur beyond 2 months of the infusions, this open study provides evidence that infliximab is an effective treatment.
Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis.
TLDR
The data suggest that infliximab may provide an effective and more specific therapeutic option in the treatment of active Wegener's granulomatosis refractory to standard treatment.
...
1
2
3
4
5
...